Literature DB >> 21077737

Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010.

Michel Meignan1, Andrea Gallamini, Corinne Haioun, Aaron Polliack.   

Abstract

One hundred and fifty hemato-oncologists and nuclear medicine specialists from more than 20 countries joined in April 2010 the 2-day Second International Workshop on interim PET in lymphoma. During the nuclear medicine session the advantages of the five-point scale Deauville criteria for interim PET reporting over the other sets of visual criteria were presented. The specific problems of PET reporting in escalation/de-escalation trials in Hodgkin lymphoma (HL) were addressed as well as the limitations of visual analysis for early PET evaluation in non-Hodgkin lymphoma (NHL). The applicability, efficacy, and reproducibility of quantitative criteria (ΔSUV(max) analysis and tumor/liver SUV ratio) for interim PET in NHL were reported. In retrospective and prospective series. Some of the interim PET-based clinical trials ongoing worldwide in HL and NHL were reported. In early-stage HL, three trials aimed at determining the feasibility of omitting radiotherapy in interim PET negative patients, and in advanced-stage HL two PET-based ABVD escalation or BEACOPP de-escalation trials, in NHL two studies reported preliminary results of interim PET in follicular lymphoma, in DLBCL a round-table discussion pointed out the lack of definite criteria for interim PET, and a few observational studies in DLBCL reported the comparison of the various techniques of interim PET reporting (visual versus quantitative). The preliminary results of two international validation studies of the five-point scale criteria in HL and NHL launched in 2009 were reported. The presentations of the meeting are available on http://eitti.free.fr.

Entities:  

Mesh:

Year:  2010        PMID: 21077737     DOI: 10.3109/10428194.2010.529208

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  41 in total

1.  Qualitative interpretation of PET scans using a Likert scale to assess neck node response to radiotherapy in head and neck cancer.

Authors:  Johanna Sjövall; Ulrika Bitzén; Elisabeth Kjellén; Per Nilsson; Peter Wahlberg; Eva Brun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-02       Impact factor: 9.236

2.  Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.

Authors:  Mark Hertzberg; Maher K Gandhi; Judith Trotman; Belinda Butcher; John Taper; Amanda Johnston; Devinder Gill; Shir-Jing Ho; Gavin Cull; Keith Fay; Geoff Chong; Andrew Grigg; Ian D Lewis; Sam Milliken; William Renwick; Uwe Hahn; Robin Filshie; George Kannourakis; Anne-Marie Watson; Pauline Warburton; Andrew Wirth; John F Seymour; Michael S Hofman; Rodney J Hicks
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941

3.  The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy.

Authors:  Xingchen Wu; Abhisek Bhattarai; Pasi Korkola; Hannu Pertovaara; Hannu Eskola; Pirkko-Liisa Kellokumpu-Lehtinen
Journal:  Mol Imaging Biol       Date:  2017-10       Impact factor: 3.488

4.  Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma.

Authors:  Dong Won Baek; Hee Jeong Cho; Ju-Hyung Kim; Sang Kyun Sohn; Ga-Young Song; Seo-Yeon Ahn; Sung-Hoon Jung; Jae Sook Ahn; Je-Jung Lee; Hyeoung-Joon Kim; Shin-Young Jeong; Chae Moon Hong; Jung-Joon Min; Joon-Ho Moon; Deok-Hwan Yang
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

5.  The prognostic value of PET/CT evaluation with Deauville score on the recurrence and survival in diffuse large B-cell lymphoma: a multi-institutional study of KROG 17-02.

Authors:  Jeong Won Lee; Dongryul Oh; Keun-Yong Eom; Jin Hee Kim; Woo Chul Kim; Mi Joo Chung; Jong Hoon Lee
Journal:  Clin Exp Metastasis       Date:  2019-09-25       Impact factor: 5.150

Review 6.  The evolving role of response-adapted PET imaging in Hodgkin lymphoma.

Authors:  Michael Coyle; Lale Kostakoglu; Andrew M Evens
Journal:  Ther Adv Hematol       Date:  2016-04

Review 7.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

8.  Predictive value of 18F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial.

Authors:  Stéphanie Becker; Thomas Vermeulin; Anne-Ségolène Cottereau; Nicolas Boissel; Pierre Vera; Stéphane Lepretre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-21       Impact factor: 9.236

9.  PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study.

Authors:  Christelle Tychyj-Pinel; Fabien Ricard; Michael Fulham; Marion Fournier; Michel Meignan; Thierry Lamy; Pierre Vera; Gilles Salles; Judith Trotman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

10.  Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.

Authors:  Domenico Albano; Giovanni Bosio; Chiara Pagani; Alessandro Re; Alessandra Tucci; Raffaele Giubbini; Francesco Bertagna
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-02       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.